Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Placebo ELLIPTA;   Drug: Nemiralisib ELLIPTA 50 µg;   Drug: Nemiralisib ELLIPTA 100 µg;   Drug: Nemiralisib ELLIPTA 250 µg;   Drug: Nemiralisib ELLIPTA 500 µg;   Drug: Nemiralisib ELLIPTA 750 µg;   Drug: Albuterol (Salbutamol) MDI or nebules;   Drug:  Standard of care therapy Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials